- Home
- BJDX vs ZVSA Comparison
BJDX vs ZVSA Comparison
Compare BJDX & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- ZVSA
- Stock Information
- Founded
- BJDX 2015
- ZVSA 2014
- Country
- BJDX United States
- ZVSA United States
- Employees
- BJDX N/A
- ZVSA N/A
- Industry
- BJDX Medical Specialities
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- ZVSA Health Care
- Exchange
- BJDX Nasdaq
- ZVSA Nasdaq
- Market Cap
- BJDX 1.8M
- ZVSA 1.5M
- IPO Year
- BJDX 2021
- ZVSA N/A
- Fundamental
- Price
- BJDX $3.35
- ZVSA $1.42
- Analyst Decision
- BJDX
- ZVSA Strong Buy
- Analyst Count
- BJDX 0
- ZVSA 1
- Target Price
- BJDX N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- BJDX 149.2K
- ZVSA 2.2M
- Earning Date
- BJDX 11-07-2024
- ZVSA 11-14-2024
- Dividend Yield
- BJDX N/A
- ZVSA N/A
- EPS Growth
- BJDX N/A
- ZVSA N/A
- EPS
- BJDX N/A
- ZVSA N/A
- Revenue
- BJDX N/A
- ZVSA N/A
- Revenue This Year
- BJDX N/A
- ZVSA N/A
- Revenue Next Year
- BJDX N/A
- ZVSA N/A
- P/E Ratio
- BJDX N/A
- ZVSA N/A
- Revenue Growth
- BJDX N/A
- ZVSA N/A
- 52 Week Low
- BJDX $3.03
- ZVSA $0.98
- 52 Week High
- BJDX $388.00
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- BJDX 42.75
- ZVSA 57.25
- Support Level
- BJDX $3.30
- ZVSA $1.31
- Resistance Level
- BJDX $3.67
- ZVSA $1.95
- Average True Range (ATR)
- BJDX 0.37
- ZVSA 0.19
- MACD
- BJDX -0.05
- ZVSA 0.04
- Stochastic Oscillator
- BJDX 2.94
- ZVSA 44.21
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.